DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Category OMER
Omeros Corp
Omeros ( $OMER ): the post-approval story is finally turning, early commercial momentum is here, and the next upside chapter may be starting
The new March 31, 2026 press release did not simply deliver an earnings update. It effectively marked the first real post-approval checkpoint for Omeros. The company is no longer only a regulatory event story. After the December 23, 2025 FDA approval of YARTEMLEA for TA-TMA and the January 2026 U.S. launch, the central question has changed. The market is now asking whether the company can convert medical need, regulatory exclusivity and first-mover status into a durable commercial franchise.
Omeros Corporation ( $OMER ) YARTEMLEA launch, balance-sheet reset, and the real execution test
Omeros is no longer primarily a regulatory story. That phase changed materially on December 23, 2025, when the FDA approved YARTEMLEA for hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and pediatric patients aged two and older. From that point forward, the central question stopped being “can they get this approved?” and became “can they turn a highly specialized approval into durable commercial traction inside a very concentrated transplant market?”
OMER Omeros Corporation
What happened in January: Omeros successfully transitioned from pre-commercial biotech to commercial-stage rare disease company with the FDA approval of YARTEMLEA on December 23, 2025 and first commercial sales announced January 27, 2026.
OMER – Omeros – YARTEMLEA TA-TMA launch
Short update on Omeros after the FDA approval of YARTEMLEA (narsoplimab-wuug) for TA-TMA, the start of the U.S. launch and the analyst upgrades published in early January 2026. For the full story, background and detailed scenarios, see the main OMER reports on Merlintrader.
OMER The Plan
DA approval is in the bag, pricing is out in the open, and the call with transplant KOLs was basically a long “here’s how we want to own TA-TMA”. Let’s unpack what Omeros is really trying to do with YARTEMLEA, beyond the usual headline noise.
OMER Omeros Corp 2026
After years of being treated as a “show-me story”, Omeros enters 2026 with two key green lights: FDA approval of Yartemlea (narsoplimab-wuug) and a large strategic deal with Novo Nordisk on OMS906. This report walks through the approval process, current US/EU regulatory status, the financial impact of the Novo deal, and a catalyst map for 2026.
OMER Omeros Corp
News of the day – FDA approval
The FDA has approved YARTEMLEA (narsoplimab-wuug) for treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children 2 years and older. YARTEMLEA is the first and only approved inhibitor of the lectin complement pathway and the only FDA-approved therapy for TA-TMA.
OMER Omeros Corp Yartemlya (narsoplimab)
This article is built around one simple idea: before the label is public, you can only discuss “expectations” seriously if you anchor them to official sources, peer-reviewed evidence, and observable regulatory patterns. This is not a “tip.” It is a disciplined reading exercise.
OMER Omeros: The Finish Line Approaches
Omeros Corporation is approaching a binary regulatory event: the U.S. Food and Drug Administration (FDA) is scheduled to decide on the Biologics License Application (BLA) for narsoplimab (to be marketed as Yartemlya) in hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) on December 26, 2025. This is the company’s most important near-term catalyst and one of the most closely watched PDUFAs into year-end.
OMER The Path of the Force Update dec 9
Omeros Corporation is a US-based biotechnology company focused on complement-related diseases. Its lead asset, narsoplimab (OMS721), targets transplant-associated thrombotic microangiopathy (TA-TMA), with a PDUFA target action date of December 26, 2025 for its resubmitted BLA. This is the core binary catalyst currently driving the stock.
⚡ “OMER — The Biotech Force Awakens”
⚡ “OMER — The Biotech Force Awakens”
$Omer a sleeping giant…
Omer è un gigante che aspetta di svegliarsi. Assopito ma fino a quando? considerando le più che buone notizie avute poco tempo fà con l'accordo con Novo, non ci metterà molto a reagire al declino di questi ultimi giorni senza grossi volumi.
$OMER
OMER si trova in un punto perfetto per un possibile assestamento dopo il rintracciamento degli tultimi giorni a seguito dello spike fini a 13 il giorno delle news dell'accordo con Novo. Se tiene il supporto da qui la ripartenza verso fine dicembre , 26 dicembre Pdufa.
$OMER
Oggi Omer ha siglato una partership con Novo Nordisk molto buona, con upfront che dovrebbe evitare diluzoni prima dell'eventuale approvazione. Giustificando il salto nel prezzo. Ora da qui a dicembre un runup è verosimile. Le prossime resitenze stanno nel grafico. Sicuramente una possibilità da considerare il runup qui, stando attenti a scegliere bene ingresso ed uscita.